354 related articles for article (PubMed ID: 26294075)
1. Novel treatment options for juvenile idiopathic arthritis.
Steigerwald KA; Ilowite NT
Expert Rev Clin Pharmacol; 2015; 8(5):559-73. PubMed ID: 26294075
[TBL] [Abstract][Full Text] [Related]
2. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
[TBL] [Abstract][Full Text] [Related]
3. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
[TBL] [Abstract][Full Text] [Related]
4. Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
Burnett HF; Ungar WJ; Regier DA; Feldman BM; Miller FA
Value Health; 2014 Dec; 17(8):830-7. PubMed ID: 25498778
[TBL] [Abstract][Full Text] [Related]
5. Juvenile idiopathic arthritis in the new world of biologics.
Ostring GT; Singh-Grewal D
J Paediatr Child Health; 2013 Sep; 49(9):E405-12. PubMed ID: 23647810
[TBL] [Abstract][Full Text] [Related]
6. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
7. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
[TBL] [Abstract][Full Text] [Related]
8. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.
Wahezi DM; Ilowite NT
Expert Opin Pharmacother; 2013 Jun; 14(8):975-89. PubMed ID: 23528005
[TBL] [Abstract][Full Text] [Related]
9. [Current therapy of polyarticular forms of juvenile idiopathic arthritis].
Hospach A; Rühlmann JM; Weller-Heinemann F
Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055
[TBL] [Abstract][Full Text] [Related]
10. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.
Ho ACH; Wong SN; Leung LCK; Chan WKY; Chong PCY; Tse NKC; Yeung RHM; Kong SY; Lee KP
Hong Kong Med J; 2020 Feb; 26(1):56-65. PubMed ID: 32077861
[TBL] [Abstract][Full Text] [Related]
11. Juvenile idiopathic arthritis overview and involvement of the temporomandibular joint: prevalence, systemic therapy.
Carrasco R
Oral Maxillofac Surg Clin North Am; 2015 Feb; 27(1):1-10. PubMed ID: 25483440
[TBL] [Abstract][Full Text] [Related]
12. Investigational drugs for treatment of juvenile idiopathic arthritis.
Mauro A; Rigante D; Cimaz R
Expert Opin Investig Drugs; 2017 Apr; 26(4):381-387. PubMed ID: 28277884
[TBL] [Abstract][Full Text] [Related]
13. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
14. Juvenile idiopathic arthritis - what the clinician needs to know.
Kahn PJ
Bull Hosp Jt Dis (2013); 2013; 71(3):194-9. PubMed ID: 24151944
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids in juvenile idiopathic arthritis.
Malattia C; Martini A
Ann N Y Acad Sci; 2014 May; 1318():65-70. PubMed ID: 24738483
[TBL] [Abstract][Full Text] [Related]
16. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
17. Updates in Juvenile Idiopathic Arthritis.
McCurdy D; Parsa MF
Adv Pediatr; 2021 Aug; 68():143-170. PubMed ID: 34243850
[No Abstract] [Full Text] [Related]
18. Dosing regimen determination for juvenile idiopathic arthritis: a review of studies during drug development.
Ji P; Chowdhury BA; Yim S; Sahajwalla CG
J Pharm Sci; 2012 Aug; 101(8):2621-34. PubMed ID: 22653876
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
[TBL] [Abstract][Full Text] [Related]
20. Managing juvenile idiopathic arthritis-associated uveitis.
Hawkins MJ; Dick AD; Lee RJ; Ramanan AV; Carreño E; Guly CM; Ross AH
Surv Ophthalmol; 2016; 61(2):197-210. PubMed ID: 26599495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
